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Abstract  
Peripheral T-cell lymphomas (PTCL) are classified as mature T-cell neoplasms. However, several new 
findings support the notion that premalignant cells arise in the immature stage of hematopoietic 
differentiation, and subsequently evolve into full-blown T-lineage tumor cells. Acquisition of TET2 
mutations may be an important event for the establishment of premalignant cells. In PTCL harboring 
features of follicular helper T cells, tumor-specific G17V RHOA mutations co-occur with premalignant 
TET2 mutations. The G17V RHOA mutations may play important roles in clonal evolution of 
premalignant cells into tumor cells. Indeed, multistep tumorigenesis is thought to be essential for 
pathogenesis of PTCL.   
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Introduction 
Recent advances in sequencing technologies led to the discovery of gene mutations in epigenetic 
regulators, including Ten-Eleven Translocation 2 (TET2)1, DNA methyltransferase 3A (DNMT3A)2, and 
isocytrate dehydrogenease 1/2 (IDH1/2) 3 in hematologic malignancies. These gene mutations were first 
identified in myeloid malignancies1-3. Subsequently, they were also found in lymphoid malignancies4-6. 
The mutation frequencies were especially high in peripheral T-cell lymphoma (PTCL) with features of 
follicular helper T (Tfh) cells, that is angioimmunoblastic T-cell lymphoma (AITL) and a subtype of 
peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS)4-9. 
An intriguing observation was that these mutations were detected in premalignant cells as well as 
tumor cells4, 5, 8, 10-12. Additionally, distinct mutations for each disease were found in the full-blown tumor 
cells8, 10, 12. That is, the stepwise accumulation of mutations might contribute to the development of tumor 
cells. This review will especially focus on the multistep tumorigeneis in PTCL from a genetic point of 
view.  
 
Origins of TET2 and DNMT3A mutations in PTCL 
In some cases of PTCL, TET2 and DNMT3A mutations were identified not only in the T-lineage tumor 
cells but also in non-tumor hematopoietic cells, including B and myeloid cells as well as myeloid 
progenitors4, 5, 8. These data suggest that the mutations occurred in hematopoietic stem/ multipotent 
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hematopoietic progenitors in PTCL4, 5, 8. In other words, the origins of PTCL are in the immature stage of 
hematopoietic differentiation although the full-blown tumor cells have characteristics of terminally 
differentiated T-lineage cells.   
TET2 and DNMT3A mutations were also detected in apparently normal hematopoietic stem cells 
(HSCs) in the leukemic phase and those at the remission state in acute myeloid leukemia (AML) 10-12. 
Occasionally, both lymphoid and myeloid malignancies occurred simultaneously or serially in a patient. It 
has been reported that identical TET2 and/or DNMT3A mutations were detected in specimens of each 
disease in a case with B-cell lymphoma and AML4, and cases with AITL and myelodysplastic syndrome5. 
These data further support the notion that TET2 and DNMT3A mutations may reside in premalignant cells 
in a wide variety of hematopoietic malignancies in addition to PTCL. 
During the aging process, a part of the blood system, especially the myeloid compartment, is 
occasionally replaced by cells originating from a clone13, 14. The mechanisms of clonal hematopoiesis are 
yet to be elucidated. Darwinism may explain why it occurs; one cell obtains advantages for survival over 
other cells; then, selection pressure accelerates substitution in the blood system by its clones.  
Remarkably, TET2 mutations were observed in 5.6% of normal elderly individuals with non-random 
X-chromosome inactivation16. TET2-mutant allele burden revealed close concordance with the degree of 
skewing determined by the X-inactivation patterns15. It means that TET2-mutant allele burden might 
reflect the clonal size of blood cells15. Subsequently, recurrent mutations in DNMT3A as well as other 
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leukemia and/or lymphoma-associated genes were also reported in the blood cells of elderly individuals 
without hematologic malignancies16-18. The allele frequencies of the mutations were low in a substantial 
number of cases, possibly in the early stages of clonal expansion16.  
The functions of TET2 and DNMT3A genes in the blood system have been extensively examined in 
knockout mouse studies. It has been reported by several groups that deletion of TET2 in mice leads to an 
increase in the self-renewal capacity of hematopoietic stem cells (HSC)4, 19-22. Deletion of DNMT3A also 
enhances the self-renewal capacity, while it markedly inhibits cellular differentiation23. 
Given the results of knockout mouse experiments, functional impairment of TET2 or DNMT3A by 
gene mutations would give superiority to the mutation-bearing cells over non-mutated cells, and 
contribute to the establishment of clonal hematopoiesis during aging. Finally, the mutation-bearing 
hematopoietic progenitors may evolve into preleukemic/prelymphoma stem cells (Figure1). In fact, the 
presence of somatic mutations in the blood was associated with significantly higher risk of hematologic 
malignancies17, 18, while impact of these mutations on incidence of PTCL remains to be elucidated.  
 
Clonal evolution of mutation-bearing prelymphoma cells 
Both myeloid and lymphoid malignancies can emerge from TET2-or DNMT3A-mutated 
preleukemic/lymphoma stem cells (Figure1). So, what kinds of mechanisms are required for the 
development of each disease?  
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Gene mutations in myeloid malignancies have been extensively analyzed since the 1980s. First, 
mutations in neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) were discovered in 
myelodysplastic syndrome in 198724. Subsequently, mutations in fms related tyrosine kinase3 (FLT3)25, 
CCAAT/enhancer binding protein (C/EBP), alpha26, and nucleophomin (NPM1)27 were identified in AML. 
To date, mutations have been identified in more than 100 genes28-30, most of which are known to be 
essential in the differentiation and proliferation/apoptosis of myeloid cells. 
In contrast, the mutational profiles of PTCL were not elucidated until very recently. By 
comprehensive gene-mutation analysis, we and others found novel recurrent mutations in ras homolog 
family member A (RHOA) in PTCL with features of Tfh cells: 53-71% of AITL8, 9, 31 and 62% of 
AITL-like PTCL-NOS8. Most of the RHOA mutations found in PTCL were confined to c. 50G>T, 
resulting in conversion from glycine to valine at the 17th position of the RHOA protein8, 9, 31.  
    RHOA mutations were also reported in 8.5% of Burkitt lymphoma, though the distribution of 
mutations was different from those in PTCL32. The RHOA mutations in Burkitt lymphoma were 
concentrated at c.14C>G, resulting in conversion from arginine to glutamine at the 5th position, while 
G17V RHOA mutations were not detected32. Also, G17V RHOA mutations were not detected in myeloid 
malignancies or other B-cell malignancies in our cohort8.  
Remarkably, the RHOA-mutated samples had the TET2 mutations8. The coexistence of the RHOA 
and TET2 mutations suggests that the crosstalk of these mutations might contribute to the pathogenesis of 
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AITL.  
As described, TET2 mutations existed in the preleukemic/prelymphoma cells. The allele frequencies 
of the RHOA mutations were statistically lower than those of the TET2 mutations in the samples with both 
mutations8. These data suggest that the G17V RHOA mutations occurred later than the TET2 mutations. 
Furthermore, RHOA mutations were not detected in the non-tumor hematopoietic cells, whereas TET2 
mutations were detected both in tumor cells and non-tumor hematopoietic cells8.    
    From these pieces of genetic evidence, it seems likely that G17V RHOA mutations play a main role 
in the development of PTCL with features of Tfh cells. The G17V RHOA mutations in TET2-mutated 
prelymphoma cells may facilitate the selective differentiation of these cells into Tfh-like tumor cells 
(Figure1). 
 
Functions of the G17V RHOA mutants 
As described above, RHOA mutations might play an essential role in the multistep tumorigenesis of 
PTCL8. RHOA is a small GTPase, cycling between an active GTP-bound state and an inactive 
GDP-bound state33. The activation of RHOA is mediated by guanine exchange factors (GEFs)33. The 
G17V RHOA mutant cannot bind GTP and exhibits defective RHOA signaling in the cells8, 9, 31. The roles 
of the G17V RHOA mutant in AITL development have not been clarified. Inhibition of RHOA signaling 
by expressing C3 transferase, an inhibitor of RHO signaling under the lck promoter, was reported to 
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provoke fatal T-cell malignancies in mice34.    
  Recently, frequent RHOA mutations were reported in diffuse-type gastric cancers35-37. The RHOA 
mutations in gastric cancers resulted in defective RHOA signaling in the cells37, although the hotspot sites 
of RHOA mutations in gastric cancers were different from those in AITL35-37. Genetic alterations of 
RHOA might have functional properties for cancer development greater than expected. 
  
Coexistence of TET2 and DNMT3A mutations in prelymphoma cells 
Eventually, both of TET2 and DNMTA, frequently mutated in prelymphoma cells in PTCL, encode DNA 
modifying enzymes. The downstream molecular events of these mutations in prelymphoma cells are 
unclear.  
TET2 encodes a methylcytosine dioxygenase, converting methylcytosine to hydroxymethylcytosine, 
formylcytosine, and carboxylcytosine38-40. One of the functions of TET2 is thought to be to mediate the 
demethylation process. On the other hand, DNMT3A encodes a methylcytosine transferase, converting 
cytosine to methylcytosine. Considering the physiological functions of these epigenetic regulators, 
loss-of-function mutations in these genes might have the opposite roles in the DNA methylation process. 
Epigenetic profiles of TET2- or -DNMT3A- mutated tumors in myeloid malignancies have been studied 
by several groups41-45. It is controversial whether the functional impairment of TET2/DNMT3A results in 
hypermethylation/hypomethylation 2, 41-47, respectively. Namely, the samples with TET2 mutations had 
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hypermethylation profiles in some reports 42, 44, 45, while opposite results were reported in others41, 43. In 
parallel, differential methylation patterns, either hypomethylation or hypermethylation, were observed in 
more than 3000 genomic regions between those with or without DNMT3A mutations in one report 46, 
while DNMT3A mutations were associated with hypomethylation in less than 200 genomic regions in 
another report2. Furthermore, it is more complicated for understanding that TET2 and DNMT3A mutations 
are simultaneously identified in a substantial number of samples in both PTCL8, 9 and myeloid 
malignancies28, 48, 49. Until now, there are no reports describing impact of TET2/DNMT3A mutations on 
methylation status in PTCL.  
 
IDH2 mutations; their origins and correlations with TET2 mutations  
IDH2 mutations were detected in both PTCL and myeloid malignancies although the hotspots differed 
among the diseases. In PTCL, the mutations were restricted to those affecting the R172 position6, 8, 9, 
while both R140 and R172 mutations were found in myeloid malignancies28, 50. Moreover, mutations in 
the IDH1 gene, another member of the IDH family, were detected in AML at similar frequencies to those 
of the IDH2 mutations50, while they have been rarely identified in PTCL5, 6, 8. IDH2 and TET2 mutations 
are known to be exclusive in myeloid malignancies42, 49, 51. This is explained by the hypothesis that 
2-hydroxyglutarate, which is produced by the IDH2 mutant, is known to inhibit the function of 
alpha-ketoglutarate (alpha-KG)-dependent dioxigenases, including the TET2 protein42, 52. As a result, the 
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IDH1/2-mutated and the TET2-mutated myeloid malignancies were reported to have similar 
hypermethylation patterns42. In contrast, IDH2 mutations were detected in a part of the RHOA-TET2 
mutated samples in PTCL8. The coexistence of IDH2 and TET2 mutations in PTCL suggests that the 
downstream mechanisms of IDH2 mutations in PTCL might be different from those in myeloid 
malignancies (Figure2). 
It has been reported that IDH2 mutations existed in preleukemic cells in AML10, 12. In PTCL, the 
allele frequencies of IDH2 mutations were much lower than those of TET2 mutations, suggesting that 
IDH2 mutations occur later than TET2 mutations8. In addition, IDH2 mutations were not detected in 
non-tumor hematopoietic cells in PTCL8. These data suggest that the IDH2 mutations are a relatively late 
event in most PTCL cases.  
The specific inhibitors for IDH mutants have been developed and are now under clinical trial in 
AML53. Considering the different distribution of IDH2 mutations in AML and PTCL, the clinical 
significance of the IDH inhibitors should be independently examined in PTCL.   
 
Conclusion 
For more than 20 years PTCLs have been thought to be mature T-cell malignancies. However, the origins 
of PTCLs can be tracked back to the immature stage of hematopoiesis. Specific genetic events contribute 
to clonal evolution of prelymphoma cells into characteristic tumor cells. Understanding multistep 
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tumorigenesis in PTCL will enable us to find new strategies for treating such dire diseases. 
 
Figure legends 
Figure1 Multistep tumorigenesis in PTCL  
TET2- or DNMT3A- mutated hematopoietic progenitors evolve into preleukemic/prelymphoma stem cells. 
Both myeloid and lymphoid malignancies can emerge from the preleukemic/lymphoma cells. Subsequent 
genetic events determine the cell fate of preleukemic/prelymphoma cells.  
 
Figure2 Relationship between IDH2 and TET2 mutations in hematologic malignancies 
IDH2 and TET2 mutations are known to be exclusive in myeloid malignancies, because the IDH2 mutants 
contribute to myeloid malignancies through inhibition of TET2 function. The coexistence of IDH2 and 
TET2 mutations in PTCL suggests that the targets of the IDH2 mutants in PTCL might be different from 
those in myeloid malignancies. 
 
 
  
References 
1. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A, et al. 
Mutation in TET2 in myeloid cancers. N Engl J Med 2009;360:2289-301. 
12 
 
2. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. 
DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010;363:2424-33. 
3. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. 
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 
2009;361:1058-66. 
4. Quivoron C, Couronne L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O, et al. 
TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a 
recurrent event during human lymphomagenesis. Cancer Cell 2011;20:25-38. 
5. Couronne L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human 
T-cell lymphoma. N Engl J Med 2012;366:95-6. 
6. Cairns RA, Iqbal J, Lemonnier F, Kucuk C, de Leval L, Jais JP, et al. IDH2 
mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 2012;119:1901-3. 
7. Lemonnier F, Couronne L, Parrens M, Jais JP, Travert M, Lamant L, et al. 
Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features 
and adverse clinical parameters. Blood 2012;120:1466-9. 
8. Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y, et al. 
Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 2014;46:171-5. 
9. Palomero T, Couronne L, Khiabanian H, Kim MY, Ambesi-Impiombato A, 
Perez-Garcia A, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase 
in peripheral T cell lymphomas. Nat Genet 2014;46:166-70. 
10. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, et al. 
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 
2014;506:328-33. 
11. Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL, Quake SR, et al. 
Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid 
leukemia. Sci Transl Med 2012;4:149ra18. 
12. Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. 
Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and 
persist in remission. Proc Natl Acad Sci U S A 2014;111:2548-53. 
13. Busque L, Mio R, Mattioli J, Brais E, Blais N, Lalonde Y, et al. Nonrandom 
X-inactivation patterns in normal females: lyonization ratios vary with age. Blood 
1996;88:59-65. 
14. Gale RE, Fielding AK, Harrison CN, Linch DC. Acquired skewing of X-chromosome 
inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age. 
Br J Haematol 1997;98:512-9. 
15. Busque L, Patel JP, Figueroa ME, Vasanthakumar A, Provost S, Hamilou Z, et al. 
13 
 
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. 
Nat Genet 2012;44:1179-81. 
16. Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, et al. Age-related 
mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 
2014;20:1472-8. 
17. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. 
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes. N Engl J Med 2014. 
18. Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. 
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence. N Engl J 
Med 2014. 
19. Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, et al. 
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid 
transformation. Cancer Cell 2011;20:11-24. 
20. Ko M, Bandukwala HS, An J, Lamperti ED, Thompson EC, Hastie R, et al. 
Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of 
hematopoietic stem cells in mice. Proc Natl Acad Sci U S A 2011;108:14566-71. 
21. Kunimoto H, Fukuchi Y, Sakurai M, Sadahira K, Ikeda Y, Okamoto S, et al. Tet2 
disruption leads to enhanced self-renewal and altered differentiation of fetal liver 
hematopoietic stem cells. Sci Rep 2012;2:273. 
22. Shide K, Kameda T, Shimoda H, Yamaji T, Abe H, Kamiunten A, et al. TET2 is 
essential for survival and hematopoietic stem cell homeostasis. Leukemia 2012;26:2216-23. 
23. Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS, et al. Dnmt3a is essential 
for hematopoietic stem cell differentiation. Nat Genet 2012;44:23-31. 
24. Hirai H, Kobayashi Y, Mano H, Hagiwara K, Maru Y, Omine M, et al. A point 
mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome. Nature 
1987;327:430-2. 
25. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, et al. Internal 
tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 
1996;10:1911-8. 
26. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, et al. 
Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha 
(C/EBPalpha), in acute myeloid leukemia. Nat Genet 2001;27:263-70. 
27. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. 
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N 
Engl J Med 2005;352:254-66. 
28. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N 
14 
 
Engl J Med 2013;368:2059-74. 
29. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. 
Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 
2011;478:64-9. 
30. Naoe T, Kiyoi H. Gene mutations of acute myeloid leukemia in the genome era. Int 
J Hematol 2013;97:165-74. 
31. Yoo HY, Sung MK, Lee SH, Kim S, Lee H, Park S, et al. A recurrent inactivating 
mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet 2014. 
32. Rohde M, Richter J, Schlesner M, Betts MJ, Claviez A, Bonn BR, et al. Recurrent 
RHOA mutations in pediatric Burkitt lymphoma treated according to the NHL-BFM 
protocols. Genes Chromosomes Cancer 2014. 
33. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 
2002;420:629-35. 
34. Cleverley SC, Costello PS, Henning SW, Cantrell DA. Loss of Rho function in the 
thymus is accompanied by the development of thymic lymphoma. Oncogene 2000;19:13-20. 
35. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 
2014. 
36. Kakiuchi M, Nishizawa T, Ueda H, Gotoh K, Tanaka A, Hayashi A, et al. Recurrent 
gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet 
2014;46:583-7. 
37. Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi ST, et al. Whole-genome sequencing 
and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat 
Genet 2014;46:573-82. 
38. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, et al. 
Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL 
partner TET1. Science 2009;324:930-5. 
39. He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q, et al. Tet-mediated formation of 
5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011;333:1303-7. 
40. Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, et al. Tet proteins can 
convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 
2011;333:1300-3. 
41. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, et al. 
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 
2010;468:839-43. 
42. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al. Leukemic 
IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, 
15 
 
and impair hematopoietic differentiation. Cancer Cell 2010;18:553-67. 
43. Perez C, Martinez-Calle N, Martin-Subero JI, Segura V, Delabesse E, 
Fernandez-Mercado M, et al. TET2 mutations are associated with specific 5-methylcytosine 
and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia. 
PLoS One 2012;7:e31605. 
44. Yamazaki J, Taby R, Vasanthakumar A, Macrae T, Ostler KR, Shen L, et al. Effects 
of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics 
2012;7:201-7. 
45. Nischal S, Bhattacharyya S, Christopeit M, Yu Y, Zhou L, Bhagat TD, et al. 
Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of 
myeloproliferative neoplasms. Cancer Res 2013;73:1076-85. 
46. Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y, et al. Exome sequencing identifies 
somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. 
Nat Genet 2011;43:309-15. 
47. Yamazaki J, Issa JP. Epigenetic aspects of MDS and its molecular targeted therapy. 
Int J Hematol 2013;97:175-82. 
48. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al. 
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 
2014;28:241-7. 
49. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. 
Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 
2013;122:3616-27; quiz 99. 
50. Dang L, Jin S, Su SM. IDH mutations in glioma and acute myeloid leukemia. 
Trends Mol Med 2010;16:387-97. 
51. Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, 
et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin 
Oncol 2013;31:2428-36. 
52. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, et al. Oncometabolite 
2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent 
dioxygenases. Cancer Cell 2011;19:17-30. 
 
53.      Stein E, Tallman M, Pollyea DA, Flinn IW, Fathi AT, Stone RM, et al. Clinical 
safety and activity in a Phase I trial of AG-221, a first in class, potent inhibitor of the 
IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic 
malignancies. Presented at: 2014 AACR Annual Meeting; April 5-9, 2014; San Diego, 
CA. Abstract CT103.  
16 
 
 
 
Fig. 1 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 
